Company History

Michael Siani-Rose and H. Martin Lades, Ph.D. founded Theregen in 2003. The two founders shared an interest in cell-based regenerative medicine and its therapeutic potential for treating numerous diseases. Research led the co-founders to the cell-based therapies addressing cardiovascular disease of the former company Advanced Tissue Sciences (ATS).

In 2004, the company (formerly Iken) acquired worldwide exclusive rights to the ATS Cardiovascular Profile, including Anginera technology and a supply agreement for manufactured tissue for clinical trials. Anginera is essentially the same product as Dermagraft™, a wound repair patch developed by ATS and marketed for diabetic foot ulcers.

In 2005 the U.S. Food and Drug Administration approved Theregen's Investigational New Drug application (IND) to conduct a Phase 1 safety trial for use of Anginera as an adjunct therapy to coronary arterial bypass graft (CABG) surgery. The Company then received additional private funding to conduct the studies. In 2006 Theregen announced the application of Anginera to its first Phase I patient, thereby moving into a promising new phase of clinical and business development in regenerative medicine.